Quarterly ResultAug 13, 2026, 04:46 PM
Tempest Reports Q2 2026 Results, New CAR-T Partnership & Pipeline Update
AI Summary
Tempest Therapeutics reported its second quarter 2026 financial results, showing a net loss of $5.2 million and cash and cash equivalents of $0.8 million. The company also provided a business update, highlighting a new development collaboration with Senlang Biotechnology for its next-generation in vivo CAR-T product candidate, TPST-4003, with first patient dosing expected in Q4 2026. Additionally, positive interim results were reported for TPST-2003, showing a 100% complete response rate in certain patient populations, and two new independent directors were appointed to the Board.
Key Highlights
- Cash and cash equivalents were $0.8 million as of June 30, 2026, down from $7.7 million on December 31, 2025.
- Net loss for Q2 2026 was $5.2 million ($0.34 per share), compared to $7.9 million ($2.07 per share) for Q2 2025.
- Research and development expenses decreased to $1.8 million in Q2 2026 from $3.9 million in Q2 2025.
- Executed a development collaboration with Senlang Biotechnology for TPST-4003, with first patient dosing anticipated in Q4 2026.
- TPST-2003 reported 100% complete response rate among 15 CAR-T-naïve patients in REDEEM-1 and POEMS-1 trials.
- Appointed Drake Richey and John Yee, MD, MPH, to the Board of Directors.
- Received approximately $2 million in gross proceeds from the inducement of certain outstanding warrants.
Price Impact
More from TPST